Cervical cancer: Are there potential new targets? an update on preclinical and clinical results

Current Drug Targets

Volumn 15, Issue 12, 2014, Pages 1107-1120

  Tomao, Federica ^a   Di Tucci, Chiara ^a   Imperiale, Ludovica ^a   Boccia, Serena Maria ^a   Marchetti, Claudia ^a   Palaia, Innocenza ^a   Muzii, Ludovico ^a   Panici, Pierluigi Benedetti ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cervical cancer; Molecular pathways; Preclinical studies; Targeted therapies

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BRIVANIB; CANCER VACCINE; CELECOXIB; CETUXIMAB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LAPATINIB; LAPATINIB PLUS PAZOPANIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; PROTEASOME INHIBITOR; RETINOID; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE MAGNESIUM; VALPROIC ACID; VASCULOTROPIN; VORINOSTAT; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); FEMALE; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; UTERINE CERVICAL NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84926283854     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141010145547     Document Type: Article

References (99)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
2. Friedlander ML, Atkinson K, Coppleson JV, et al. The integration of chemotherapy into the management of locally advanced cervical cancer: a pilot study. Gynecol Oncol 1984; 19(1): 1-7.
3. Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999; 17(9): 2676-80.
4. Hanahan. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
5. Murata T, Mizushima H, Chinen I, et al. HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancerassociated fibroblasts to support progression of uterine cervical cancers. Cancer Res. 2011; 71(21): 6633-42
6. Candelaria M, Arias-Bonfill D, Chávez-Blanco A, et al. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer. 2009 Dec; 19(9): 1632-7.
7. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7(10): 2958-70.
8. Napoletano C, Rughetti A, Landi R, et al. Immunogenicity of allovesicle carrying ERBB2 tumor antigen for dendritic cell-based antitumor immunotherapy. Int J Immunopathol Pharmacol 2009; 22(3): 647-58.
9. Conesa-Zamora P, Torres-Moreno D, Isaac MA, et al. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence. Exp Mol Pathol 2013; 95(2): 151-5.
10. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358(11): 1160-74.
11. Shintani S, Li C, Mihara M, et al. Gefinitib (‘ Iressa’, ZD 1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol 2004; 40(1): 43-51.
12. Goncalves A, Fabbro M, Lhommé C, et al. A phase II trial to evaluate gefitinib as second-or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008; 108(1): 42-6.
13. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112(3): 533-43.
14. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010; 28(22): 3562-9.
15. Craig D. Woodworth, Laura P, et al. Inhibition of the Epidermal Growth Factor Receptor by Erlotinib Prevents Immortalization of Human Cervical Cells by Human Papillomavirus Type 16. Virology 2011; 421(1): 19-27.
16. Schilder RJ, Sill MW, Lee YC, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009; 19(5): 929-33.
17. Nogueira-Rodrigues A, do Carmo CC, Viegas C, et al. Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. Clin Cancer Res 2008; 14(19): 6324-9.
18. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19(13): 3234-43.
19. Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 122(3): 495-500.
20. Farley J, Sill MW, Birrer M, et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 121(2): 303-8.
21. Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol 2009; 113(1): 16-20.
22. Hertlein L, Lenhard M, Kirschenhofer A, et al. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011; 283(1): 109-13.
23. http://clinicaltrials.gov/ct2/show/NCT00104910 [accessed October 3, 2014].
24. http://clinicaltrials.gov/show/NCT00997009 [accessed October 3, 2014].
25. http://clinicaltrials.gov/show/NCT00292955 [accessed October 3, 2014].
26. http://clinicaltrials.gov/ct2/show/NCT00292955 [accessed October 3, 2014].
27. Kersemaekers AM, van de Vijver MJ, Kenter GG, et al. Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. Genes Chromosomes Cancer 1999; 26(4): 346-54.
28. Lee CM, Shrieve DC, Zempolich KA, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005; 99(2): 415-21.
29. Chavez-Blanco A, Perez-Sanchez V, Gonzalez-Fierro A, et al. HER2 expression in cervical cancer as a potential therapeutic target. BMC Cancer 2004; 4:59.
30. Fadare O, Zheng W. HER2 protein (p185 HER2) is only rarely overexpressed in cervical cancer. Int J Gynecol Pathol 2004; 23(4): 410-1
31. Kim YM, Shin YK, Jun HJ, et al. Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor. J Radiat Res 2011; 52(6): 752-65.
32. Herrera FG, Chan P, Doll C, et al. A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. Int J Radiat Oncol Biol Phys 2007; 67(1): 97-103.
33. Gaffney DK, Winter K, Dicker AP, et al. Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys 2007; 69(1): 111-7.
34. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007; 13(17): 4964-73.
35. Janku F, Tsimberidou AM, Garrido-Laguna I, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10(3): 558-65.
36. Faried LS, Faried A, Kanuma T, et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 2008; 47(6): 446-57.
37. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010; 117(3): 473-6
38. http://clinicaltrials.gov/show/NCT01217177 [accessed October 3, 2014].
39. Borutinskaite VV, Magnusson KE, Navakauskiene R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep 2012; 39(12): 10179-86.
40. Liu N, Zhao LJ, Li XP, et al. Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNAmethyltransferase 3B. Chin Med J 2012; 125(18): 3273-8.
41. Lin Z, Bazzaro M, Wang MC, et al. Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009; 15(2): 570-7.
42. He J, Huang C, Tong A, et al. Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid. J Biosci 2008; 33(5): 715-21.
43. Takai N, Kira N, Ishii T, et al. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pac J Cancer Prev 2011; 12(3): 575-80.
44. Münster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 2007; 25(15): 1979-85.
45. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005; 4(1): 22.
46. Candelaria M, Cetina L, Pérez-Cárdenas E, et al. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol 2010; 31(4): 386-91.
47. Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebocontrolled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 2011; 28 Suppl 1: S540-6.
48. Lippman SM, Lotan R, Schleuniger U. Retinoid-interferon therapy of solid tumors. Int J Cancer 1997; 70(4): 481-3.
49. Meyskens FL Jr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 1994; 86(7): 539-43.
50. Scribner DR Jr, Benbrook DM. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol 2002; 85(1): 223-5.
51. Dürst M, Dzarlieva-Petrusevska RT, Boukamp P, et al. Molecular and cytogenetic analysis of immortalized human primary keratino cytes obtained after transfection with human papillomavirus type 16 DNA. Oncogene 1987; 1(3): 251-6.
52. Maher DM, Bell MC, O'Donnell EA, et al. Curcumin suppresses human papillomavirus oncoproteins, restores p53, Rb, and PTPN13 proteins and inhibits benzo[a]pyrene-induced upregulation of HPV E7. Mol Carcinog 2011; 50(1): 47-57.
53. S. K. Jain, N. Singh, D. Sharma, et al. A prospective study to evaluate the efficacy of curcumin in the management of advanced carcinoma cervix. J Clin Oncol 2010 ASCO Annual Meeting Abstracts. Vol 28, No 15_suppl.
54. Bruning A, Vogel M, Mylonas I, et al. Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir. Curr Cancer Drug Targets 2011 Sep; 11(7): 799-809.
55. Miyamoto Y, Nakagawa S, Wada-Hiraike O, et al. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. Oncol Rep 2013; 29(1): 51-7.
56. Jiang Y, Wang Y, Su Z, et al. Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. Mol Med Rep 2010; 3(4): 613-9.
57. Brem GJ, Mylonas I, Brüning A. Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. Gynecol Oncol. 2013; 128(2): 383-90
58. Huber A, Bai P, de Murcia JM, et al. PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development. DNA Repair 2004; 3(8-9): 1103-8.
59. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 2007; 447(7142): 346.
60. Ye F, Cheng Q, Hu Y, et al. PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma. PLoS One 2012; 7(5): e37446.
61. Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, et al. Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathol Oncol Res 2012; 18(4): 929-37
62. http://clinicaltrials.gov/show/NCT01237067 [accessed October 3, 2014].
63. http://clinicaltrials.gov/show/NCT01281852 [accessed October 3, 2014].
64. Wu XX, Kakehi Y. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin Cancer Res 2009; 15(6): 2039-47.
65. Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998; 79(3): 179-92.
66. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21(1): 21-6.
67. Cooper RA, Wilks DP, Logue JP, et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998; 4(11): 2795-800.
68. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006; 103(2): 489-93.
69. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009; 27(7): 1069-74.
70. Takano M, Kikuchi Y, Kita T, et al. Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin. Onkologie 2009; 32(10): 595-7.
71. Schefter TE, Winter K, Kwon JS, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys 2012; 83(4): 1179-84.
72. Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013; 130(1): 64-8.
73. Tewari KS, Sill M, Long HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: A phase III randomized trial of the Gynecologic Oncology Group. J Clin Oncol, 2013 ASCO Annual Meeting Abstracts. Vol 31, No 18_suppl (June 20 Supplement), 2013: 3
74. Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010; 116(2): 163-7.
75. Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2011; 29(36): 4845.
76. Bhide RS, Lombardo LJ, Hunt JT, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 2010; 9(2): 369-78.
77. http://clinicaltrials.gov/show/NCT01267253 [accessed October 3, 2014].
78. Kudelka AP, Levy T, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997; 3(9): 1501-5.
79. Ustaalioglu BB, Bilici A, Seker M, et al. Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report. Leuk Res 2010; 34(4): e108-10.
80. http://clinicaltrials.gov/show/NCT01693783 [accessed October 3, 2014].
81. http://clinicaltrials.gov/show/NCT01711515 [accessed October 3, 2014].
82. Yeh MY, Roffler SR, Yu MH. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Int J Cancer 1992; 51(2): 274-82.
83. Zou H, Wang D, Gan X, et al. Low TWEAK expression is correlated to the progression of squamous cervical carcinoma. Gynecol Oncol 2011; 123(1): 123-8.
84. Zhou H, Marks JW, Hittelman WN, et al. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther 2011; 10(7): 1276-88.
85. Zhang P, Cheetham AG, Lock LL, et al. Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug Chem 2013; 24(4): 604-13.
86. Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347(9014): 1523-7.
87. He Z, Wlazlo AP, Kowalczyk DW, et al. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 2000; 270(1): 146-61.
88. Jabbar IA, Fernando GJ, Saunders N, et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000; 18(22): 2444-53
89. Van Driel WJ, Ressing ME, Kenter GG, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999; 35(6): 946-52.
90. Steller MA, Gurski KJ, Murakami M, et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998; 4(9): 2103-9.
91. Napoletano C, Bellati F, Tarquini E, et al. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008; 198(1): 99.e1-7.
92. Chen CH, Wang TL, Hung CF, et al. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000; 18(19): 2015-22.
93. Wlazlo AP, Deng H, Giles-Davis W, et al. DNA vaccines against the human papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther 2004; 11(6): 457-64.
94. Santin AD, Hermonat PL, Ravaggi A, et al. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J Virol 1999; 73(7): 5402-10.
95. Santin AD, Bellone S, Palmieri M, et al. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 2006; 100(3): 469-78.
96. Ferrara A, Nonn M, Sehr P, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 2003; 129(9): 521-30.
97. Santin AD, Bellone S, Gokden M, et al. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002; 346(22): 1752-3.
98. Ojesina AI, Lichtenstein L, Freeman SS, et al. Landscape of Genomic Alterations in Cervical Carcinomas. Nature 2014; 506(7488): 371-5.
99. http://cancergenome.nih.gov/cancersselected/cervicalcancer [accessed October 3, 2014].